United States· US:24075-0411_22836378-d73e-4b0b-88bb-b82dd3420aab
Conjupri
A levamlodipine product containing levamlodipine maleate, registered in United States by CSPC Ouyi Pharmaceutical Co. Ltd.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LEVAMLODIPINE MALEATE
- Manufacturer
- CSPC Ouyi Pharmaceutical Co. Ltd
- Country
- United States (US)
- ATC code
- C08CA17
- ATC class
- Levamlodipine
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 6
- ndc1124075041132.5 mg in 1 BOTTLE (24075-0411-3)
- ndc1124075041152.5 mg in 1 BOTTLE (24075-0411-5)
- ndc1124075041192.5 mg in 1 BOTTLE (24075-0411-9)
- ndc1124075-0411-3
- ndc1124075-0411-5
- ndc1124075-0411-9
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
214 interactions on record for levamlodipine.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Levamlodipine · interactions on record
214 records
- 9 severe
- 203 moderate
- 2 minor
Most severe, free to view
- DolasetronA04AA04severe
- SimvastatinC10AA01severe
- CeritinibL01ED02severe
- CeritinibL01XE28severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under C08CA17
Levamlodipine, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e3f20b34-4dc6-4ff5-bd97-5fbc2fd7bc06 GET /v1/drugs/e3f20b34-4dc6-4ff5-bd97-5fbc2fd7bc06?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "2.5",
"substance": "LEVAMLODIPINE MALEATE",
"productndc": "24075-0411",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/2.5mg",
"application_number": "NDA212895",
"marketing_category": "NDA"
}See everything about levamlodipine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.